AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17855670 — intervention group
Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg once weekly)
Number of subjects: 5119
Study 17855670 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (heparin followed by vitamin K antagonist)
Number of subjects: 5119
Study 16574046 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the certainty of apprehension for DUIC
Number of subjects: 320
Study 16574046 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the severity of penalties for DUIC
Number of subjects: 320
Study 16574046 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing factual information about the accident risk associated with DUIC
Number of subjects: 320
Study 12728284 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (TNF antagonist)
Number of subjects: 265
Study 10417520 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% capsaicin applied for 60 min
Number of subjects: 22
Study 10417520 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin applied for 24 h
Number of subjects: 22
Study 10417520 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied for 24 h
Number of subjects: 22
Study 8936891 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based, nurse-administered relaxation training
Number of subjects: 26
Study 8936891 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 26
Study 1660824 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1.5 g in five or six doses over 5 days)
Number of subjects: 2
Study 1660824 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (14 or 20 g in 28 or 40 doses over 7 or 10 days)
Number of subjects: 2
Study 1660824 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (10.5 g in 21 doses over 7 days)
Number of subjects: 2
Study 1660824 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2
Study 1660824 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 2
Study 1660824 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 2
Study 7076116 — intervention group
Group type: COMPARATOR
Intervention: 10 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Number of subjects: 18
Study 7076116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5 mg per kg per day of chenodeoxycholic acid (CDCA) and 5 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Number of subjects: 18
Study 7076116 — intervention group
Group type: COMPARATOR
Intervention: 10 mg per kg per day of chenodeoxycholic acid (CDCA) for 45 to 60 days
Number of subjects: 18
Study 7076116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CDCA and UDCA
Number of subjects: 18
Study 7076116 — intervention group
Group type: COMPARATOR
Intervention: 10 mg per kg per day of chenodeoxycholic acid (CDCA)
Number of subjects: 18
Study 7076116 — intervention group
Group type: COMPARATOR
Intervention: 10 mg per kg per day of ursodeoxycholic acid (UDCA)
Number of subjects: 18
Study 31981648 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCG-2
Number of subjects: 80
Study 31981648 — intervention group
Group type: COMPARATOR
Intervention: MCCG-1
Number of subjects: 80
Study 28847198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU)
Number of subjects: 40
Study 28178589 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol presence in blood and urine during hangover state
Number of subjects: 0
Study 28178589 — intervention group
Group type: COMPARATOR
Intervention: Current consensus on cognitive testing timing
Number of subjects: 0
Study 26411467 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivalence-based instruction (EBI)
Number of subjects: 61
Study 26411467 — intervention group
Group type: COMPARATOR
Intervention: Criterion-control group (random relations)
Number of subjects: 61
Study 26411467 — intervention group
Group type: COMPARATOR
Intervention: Trial-control group (same number of trials as EBI)
Number of subjects: 61
Study 23263729 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-ion therapy with compensating boli designed for PTV1 and PTV2 at peak-exhalation phase
Number of subjects: 20
Study 21269348 — intervention group
Group type: COMPARATOR
Intervention: Melanocytes suspended in normal saline
Number of subjects: 25
Study 21269348 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanocytes suspended in patients' own serum
Number of subjects: 25
Study 21269348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 18179662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 100
Study 18179662 — intervention group
Group type: COMPARATOR
Intervention: Other second-generation antipsychotics (SGAs)
Number of subjects: 100
Study 16876044 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge
Number of subjects: 104
Study 16876044 — intervention group
Group type: COMPARATOR
Intervention: No absorbable gelatin sponge (control)
Number of subjects: 104
Study 12615625 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 lipid emulsion rich in eicosapentaenoic acid and docosahexaenoic acid
Number of subjects: 21
Study 12615625 — intervention group
Group type: COMPARATOR
Intervention: conventional (n-6) lipid emulsion (index fatty acid: arachidonic acid)
Number of subjects: 21
Study 11258587 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% oxygen enrichment of room air at simulated 5,000 m altitude
Number of subjects: 24
Study 11258587 — intervention group
Group type: COMPARATOR
Intervention: Simulated breathing air at 5,000 m
Number of subjects: 24
Study 9499495 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 (ReoPro)
Number of subjects: 520
Study 8239567 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine 5 gm p.o. and scopolamine 0.007 mg/kg IM
Number of subjects: 0
Study 8239567 — intervention group
Group type: COMPARATOR
Intervention: Lactose PO and scopolamine 0.007 mg/kg IM
Number of subjects: 0
Study 4083104 — intervention group
Group type: COMPARATOR
Intervention: 0 puffs of tobacco smoke
Number of subjects: 5
Study 4083104 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 puffs of tobacco smoke
Number of subjects: 5
Study 4083104 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 puffs of tobacco smoke
Number of subjects: 5
Study 4083104 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 puffs of tobacco smoke
Number of subjects: 5
Study 4083104 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 puffs of tobacco smoke
Number of subjects: 5
Study 29915617 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic medication review with collegial mentoring
Number of subjects: 295
Study 29915617 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 295
Study 26894924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 4545
Study 26894924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 4545
Study 26894924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4545
Study 26894924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4545
Study 26894924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 4545
Study 24935613 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Active (Wii‐Acti)
Number of subjects: 24
Study 24935613 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Family Trainer (Wii‐Train)
Number of subjects: 24
Study 24935613 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit Plus (Wii‐Fit)
Number of subjects: 24
Study 24935613 — intervention group
Group type: COMPARATOR
Intervention: 6-min walk test (6MWT)
Number of subjects: 24
Study 23538521 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 vaccine administered at 2 and 4 months of age
Number of subjects: 216
Study 23538521 — intervention group
Group type: COMPARATOR
Intervention: Maternal antibodies
Number of subjects: 216
Study 20560366 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 32
Study 20560366 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 32
Study 18390022 — intervention group
Group type: EXPERIMENTAL
Intervention: Special recruitment efforts for blacks and Hispanics at specific centers.
Number of subjects: 155000
Study 18390022 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment efforts at two centers for blacks, including one with a major special recruitment effort.
Number of subjects: 155000
Study 18390022 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment efforts at a center with a special Hispanic recruitment effort.
Number of subjects: 155000
Study 18390022 — intervention group
Group type: COMPARATOR
Intervention: Comparison of minority enrollment to age-eligible population.
Number of subjects: 155000
Study 16810506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 169
Study 16810506 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 169
Study 16810506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole and Olanzapine
Number of subjects: 169
Study 16810506 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Performance Test-Identical Pairs
Number of subjects: 169
Study 14587303 — intervention group
Group type: EXPERIMENTAL
Intervention: Val 160 mg
Number of subjects: 2002
Study 14587303 — intervention group
Group type: EXPERIMENTAL
Intervention: Val 160 mg/HCTZ 12.5 mg
Number of subjects: 2002
Study 14587303 — intervention group
Group type: EXPERIMENTAL
Intervention: Val 160 mg/HCTZ 25 mg
Number of subjects: 2002
Study 12356001 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR
Number of subjects: 0
Study 12356001 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 0
Study 10491452 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 or 1600 microg daily)
Number of subjects: 17
Study 10491452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8578093 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 0
Study 8578093 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0
Study 8578093 — intervention group
Group type: COMPARATOR
Intervention: Mixed commercial amino acids (Control)
Number of subjects: 0
Study 1790547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg orally every 12 hours for 10 days
Number of subjects: 335
Study 1790547 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 500 mg orally every six hours for 10 days
Number of subjects: 335
Study 7110300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 121
Study 7110300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 30477950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection (LLND)
Number of subjects: 328
Study 30477950 — intervention group
Group type: COMPARATOR
Intervention: Mesorectal excision alone
Number of subjects: 328
Study 29048966 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly SMS message group
Number of subjects: 332
Study 29048966 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly SMS message with response option group
Number of subjects: 332
Study 29048966 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 332
Study 27342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 0
Study 27342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (general)
Number of subjects: 0
Study 27342744 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief of OIC
Number of subjects: 0
Study 27342744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25109720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma oryzanol supplementation (600 mg/day)
Number of subjects: 30
Study 25109720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 30
Study 23045591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammostrat test (immunohistochemical multigene assay)
Number of subjects: 4598
Study 23045591 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammostrat test
Number of subjects: 4598
Study 23045591 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and exemestane treatment
Number of subjects: 4598
Study 19581222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate-partner dyads
Number of subjects: 205
Study 19581222 — intervention group
Group type: COMPARATOR
Intervention: Family-member dyads
Number of subjects: 205
Study 19581222 — intervention group
Group type: COMPARATOR
Intervention: Nonfamily-member dyads
Number of subjects: 205
Study 17468085 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil-supplemented diet
Number of subjects: 17
Study 17468085 — intervention group
Group type: COMPARATOR
Intervention: non-MCT oil diet
Number of subjects: 17
Study 16055868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg q.d.
Number of subjects: 71
Study 16055868 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg b.i.d.
Number of subjects: 71
Study 16055868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Tiotropium + Formoterol) q.d.
Number of subjects: 71
Study 12421725 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-genomic science and high throughput technologies
Number of subjects: 29000
Study 12421725 — intervention group
Group type: COMPARATOR
Intervention: Clinicopathological prognostic markers
Number of subjects: 29000
Study 9545143 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (HMG-coenzyme A reductase inhibitors)
Number of subjects: 0
Study 8006330 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g i.v. ARG (group A)
Number of subjects: 27
Study 8006330 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g i.v. ARG (group B)
Number of subjects: 27
Study 8006330 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g oral ARG (group D)
Number of subjects: 27
Study 8006330 — intervention group
Group type: COMPARATOR
Intervention: 5 g i.v. ARG (group C)
Number of subjects: 27
Study 2681560 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam + Clindamycin
Number of subjects: 454
Study 2681560 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin + Clindamycin
Number of subjects: 454
Study 1101909 — intervention group
Group type: EXPERIMENTAL
Intervention: 59iron‐sulphate‐DL‐serin combination (group B)
Number of subjects: 19
Study 1101909 — intervention group
Group type: COMPARATOR
Intervention: 59iron‐sulphate (group A)
Number of subjects: 19
Study 29486763 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling on diet and physical activity by municipal health-care staff
Number of subjects: 185
Study 29486763 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 185
Study 29486763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (counselling)
Number of subjects: 185
Study 26531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free primary closure
Number of subjects: 150
Study 26531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 150
Study 26531235 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis technique
Number of subjects: 150
Study 25515973 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric gel
Number of subjects: 47
Study 25515973 — intervention group
Group type: COMPARATOR
Intervention: Control (no gel)
Number of subjects: 47
Study 23668772 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education
Number of subjects: 468
Study 23668772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 468
Study 23668772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both physician education and patient education
Number of subjects: 468
Study 23668772 — intervention group
Group type: COMPARATOR
Intervention: Control (no education)
Number of subjects: 468
Study 20516313 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motion therapy (place-and-hold)
Number of subjects: 103
Study 20516313 — intervention group
Group type: COMPARATOR
Intervention: Passive motion therapy
Number of subjects: 103
Study 20516313 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motion therapy
Number of subjects: 103
Study 18259824 — intervention group
Group type: EXPERIMENTAL
Intervention: High dominance and low caring
Number of subjects: 167
Study 18259824 — intervention group
Group type: EXPERIMENTAL
Intervention: High dominance and high caring
Number of subjects: 167
Study 18259824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dominance and low caring
Number of subjects: 167
Study 18259824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dominance and high caring
Number of subjects: 167
Study 18259824 — intervention group
Group type: COMPARATOR
Intervention: High dominance
Number of subjects: 167
Study 18259824 — intervention group
Group type: COMPARATOR
Intervention: High caring
Number of subjects: 167
Study 16364936 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited cataract surgery (approximately 4 weeks wait)
Number of subjects: 239
Study 16364936 — intervention group
Group type: COMPARATOR
Intervention: Routine cataract surgery (12 months wait)
Number of subjects: 239
Study 14627528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin treatment
Number of subjects: 38
Study 14627528 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 38
Study 11194530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin (4 capsules BID; PhosChol 900) providing approximately 1.1 g of choline daily (2.2 g total)
Number of subjects: 12
Study 11194530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10437237 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder composed of Radix Ginseng, Radix Notoginseng and Succinum
Number of subjects: 116
Study 10437237 — intervention group
Group type: COMPARATOR
Intervention: Fufang Danshen Tablet
Number of subjects: 116
Study 8336303 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 0
Study 8336303 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion plus balanced resistive exercises
Number of subjects: 0
Study 8336303 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hand exercise (exercise groups combined)
Number of subjects: 0
Study 3534568 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal capsular polysaccharide vaccine
Number of subjects: 2295
Study 3534568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2295
Study 2681554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide plus doxorubicin (doxorubicin 60 mg/m2 by continuous push, ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna 7.5 g/m2 over 36 hours, courses every 3 weeks)
Number of subjects: 42
Study 2681554 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide plus doxorubicin
Number of subjects: 42
Study 31638936 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service (SMS) to improve medication adherence
Number of subjects: 422
Study 31638936 — intervention group
Group type: EXPERIMENTAL
Intervention: Short message service (SMS)
Number of subjects: 422
Study 29050005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (3.0g/day of NaCl)
Number of subjects: 38
Study 29050005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (18.0g/day of NaCl)
Number of subjects: 38
Study 29050005 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 38
Study 26467984 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg tramadol
Number of subjects: 60
Study 26467984 — intervention group
Group type: COMPARATOR
Intervention: 2-mL saline (control)
Number of subjects: 60
Study 23507709 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (20 mg/day)
Number of subjects: 232
Study 23507709 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rosuvastatin (2.5 mg/day)
Number of subjects: 232
Study 22409115 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one teaching with rehearsal
Number of subjects: 0
Study 22409115 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18637133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0
Study 18637133 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study 16506862 — intervention group
Group type: EXPERIMENTAL
Intervention: GXT(3‐min)
Number of subjects: 11
Study 16506862 — intervention group
Group type: EXPERIMENTAL
Intervention: GXT(5‐min)
Number of subjects: 11
Study 16506862 — intervention group
Group type: COMPARATOR
Intervention: 30‐minute TT
Number of subjects: 11
Study 12671544 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthened STD services including periodic screening and treatment for gonorrhea, chlamydial infection, trichomoniasis, bacterial vaginosis (BV), and syphilis; counseling; and supply of condoms
Number of subjects: 917
Study 12671544 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use (CCU) during follow-up
Number of subjects: 917
Study 10480041 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-hypnotic relaxation using a standardized protocol and script
Number of subjects: 56
Study 10480041 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-hypnotic relaxation
Number of subjects: 56
Study 7489421 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.15 mg.kg‐1
Number of subjects: 45
Study 7489421 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.25 mg.kg‐1
Number of subjects: 45
Study 7489421 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 1880256 — intervention group
Group type: COMPARATOR
Intervention: Photopatch test with a standard tray of 32 substances, irradiated with 10 joules/cm2 UVA after 24 hours.
Number of subjects: 1129
Study 6809322 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 36
Study 6809322 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition
Number of subjects: 36